Vitespen Completed Phase 2 Trials for Sarcomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00005628Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma